References
- Eriksson C, Rantapää-Dahlqvist S, Sundqvist K. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2013;42:260-5.
- Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009;35: 745–57.
- Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003;5:R74–81.
- Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 2012; 41:170–9.
- Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T, CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol 2010;37:257–64.
- Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2009;36:1158–65.
- Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O’Fallon WM, Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072–80.
- Lee EY, Lee ZH, Song YW. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2013;12:554–7.
- Laragione T, Brenner M, Sherry B, Gulko PS. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum 2011;63:3274–83.
- Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:1730–9.